CN1172918C - 用作抗癌剂的异噻唑衍生物 - Google Patents

用作抗癌剂的异噻唑衍生物 Download PDF

Info

Publication number
CN1172918C
CN1172918C CNB998068373A CN99806837A CN1172918C CN 1172918 C CN1172918 C CN 1172918C CN B998068373 A CNB998068373 A CN B998068373A CN 99806837 A CN99806837 A CN 99806837A CN 1172918 C CN1172918 C CN 1172918C
Authority
CN
China
Prior art keywords
ureido
isothiazole
acid amide
benzyloxy
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB998068373A
Other languages
English (en)
Chinese (zh)
Other versions
CN1303380A (zh
Inventor
E��R������ɭ
E·R·拉尔森
��˹��ŵ��
M·C·诺伊
T·G·简特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
OSI Pharmaceuticals LLC
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of CN1303380A publication Critical patent/CN1303380A/zh
Application granted granted Critical
Publication of CN1172918C publication Critical patent/CN1172918C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/58—Derivatives of thiocarboxylic acids, the doubly-bound oxygen atoms being replaced by nitrogen atoms, e.g. imino-thio ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/40—Halogenated unsaturated alcohols
    • C07C33/46—Halogenated unsaturated alcohols containing only six-membered aromatic rings as cyclic parts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CNB998068373A 1998-06-04 1999-05-03 用作抗癌剂的异噻唑衍生物 Expired - Lifetime CN1172918C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8796398P 1998-06-04 1998-06-04
US60/087,963 1998-06-04

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2004100769265A Division CN1616386A (zh) 1998-06-04 1999-05-03 用于制备异噻唑衍生物的中间体

Publications (2)

Publication Number Publication Date
CN1303380A CN1303380A (zh) 2001-07-11
CN1172918C true CN1172918C (zh) 2004-10-27

Family

ID=22208298

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB998068373A Expired - Lifetime CN1172918C (zh) 1998-06-04 1999-05-03 用作抗癌剂的异噻唑衍生物
CNA2004100769265A Pending CN1616386A (zh) 1998-06-04 1999-05-03 用于制备异噻唑衍生物的中间体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2004100769265A Pending CN1616386A (zh) 1998-06-04 1999-05-03 用于制备异噻唑衍生物的中间体

Country Status (45)

Country Link
US (4) US6235764B1 (enExample)
EP (1) EP1084114B1 (enExample)
JP (2) JP3735254B2 (enExample)
KR (1) KR100392434B1 (enExample)
CN (2) CN1172918C (enExample)
AP (1) AP1309A (enExample)
AR (1) AR016725A1 (enExample)
AT (1) ATE275553T1 (enExample)
AU (1) AU3342199A (enExample)
BG (1) BG65104B1 (enExample)
BR (1) BR9910900B1 (enExample)
CA (2) CA2333703C (enExample)
CO (1) CO5011121A1 (enExample)
CZ (1) CZ298559B6 (enExample)
DE (1) DE69920009T2 (enExample)
EA (1) EA004935B1 (enExample)
ES (1) ES2226368T3 (enExample)
GE (1) GEP20084337B (enExample)
GT (1) GT199900070A (enExample)
HN (1) HN1999000080A (enExample)
HR (1) HRP20000835B1 (enExample)
HU (1) HUP0102422A3 (enExample)
ID (1) ID27006A (enExample)
IL (1) IL138776A0 (enExample)
IS (1) IS2269B (enExample)
MA (1) MA26638A1 (enExample)
MY (1) MY130668A (enExample)
NO (1) NO318798B1 (enExample)
NZ (1) NZ507009A (enExample)
OA (1) OA11504A (enExample)
PA (1) PA8472301A1 (enExample)
PE (1) PE20000568A1 (enExample)
PL (1) PL198151B1 (enExample)
PT (1) PT1084114E (enExample)
SA (1) SA99200217B1 (enExample)
SI (1) SI1084114T1 (enExample)
SK (1) SK286405B6 (enExample)
TN (1) TNSN99106A1 (enExample)
TR (1) TR200003478T2 (enExample)
TW (1) TW561154B (enExample)
UA (1) UA60365C2 (enExample)
UY (1) UY25619A1 (enExample)
WO (1) WO1999062890A1 (enExample)
YU (1) YU70100A (enExample)
ZA (1) ZA993752B (enExample)

Families Citing this family (225)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849769A (en) * 1994-08-24 1998-12-15 Medivir Ab N-arylalkyl-N-heteroarylurea and guandine compounds and methods of treating HIV infection
AU8816298A (en) 1997-08-22 1999-03-16 Zeneca Limited Oxindolylquinazoline derivatives as angiogenesis inhibitors
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE538794T1 (de) 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP2308833A3 (en) 1999-04-15 2011-09-28 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
HN2000000051A (es) * 1999-05-19 2001-02-02 Pfizer Prod Inc Derivados heterociclicos utiles como agentes anticancerosos
CN1427839A (zh) 2000-03-16 2003-07-02 根索福特股份有限公司 含有核酸结合部分的带电荷化合物及其用途
US7078536B2 (en) 2001-03-14 2006-07-18 Genesoft Pharmaceuticals, Inc. Charged compounds comprising a nucleic acid binding moiety and uses therefor
HK1052354A1 (zh) 2000-08-09 2003-09-11 Agouron Pharmaceuticals, Inc. 吡唑-噻唑化合物，包括它们的药物组分，和他们在抑制细胞周期蛋白依赖性激酶用途的方法
US6716995B2 (en) 2000-08-17 2004-04-06 Lumera Corporation Design and synthesis of advanced NLO materials for electro-optic applications
ATE295354T1 (de) 2000-08-18 2005-05-15 Agouron Pharma Heterozyklische-hydroximino-fluorene und ihre verwendung zur inhibierung von proteinkinasen
WO2002032872A1 (fr) 2000-10-20 2002-04-25 Eisai Co., Ltd. Composes a noyau aromatique azote
YU36403A (sh) * 2000-11-28 2006-08-17 Pfizer Products Inc. Soli izotiazol-4-karboksamida kao anti-hiperproliferacioni agensi
EP1343782B1 (en) 2000-12-21 2009-05-06 SmithKline Beecham Corporation Pyrimidineamines as angiogenesis modulators
AR032028A1 (es) 2001-01-05 2003-10-22 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
WO2002083863A2 (en) 2001-04-17 2002-10-24 Sepracor, Inc. Thiazole and other heterocyclic ligands and use thereof
US6995171B2 (en) 2001-06-21 2006-02-07 Agouron Pharmaceuticals, Inc. Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents
HN2002000156A (es) 2001-07-06 2003-11-27 Inc Agouron Pharmaceuticals Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
WO2003015778A1 (en) 2001-08-17 2003-02-27 Merck & Co., Inc. Tyrosine kinase inhibitors
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20030143165A1 (en) * 2002-01-25 2003-07-31 Allan Evans NSAID-containing topical formulations that demonstrate chemopreventive activity
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
MXPA04007832A (es) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
US20040023961A1 (en) * 2002-02-11 2004-02-05 Bayer Corporation Aryl ureas with raf kinase and angiogenisis inhibiting activity
EP1503757B1 (en) 2002-05-02 2007-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
US6989451B2 (en) * 2002-06-04 2006-01-24 Valeant Research & Development Heterocyclic compounds and uses thereof
AU2003232551A1 (en) * 2002-06-13 2003-12-31 Qlt Inc. Methods of using isothiazole derivatives to treat cancer or inflammation
CA2488642C (en) 2002-06-27 2011-09-06 Dharma Rao Polisetti Aryl carbonyl derivatives as glucokinase activators
AU2003281664A1 (en) * 2002-07-25 2004-02-16 Pfizer Products Inc. Isothiazole derivatives useful as anticancer agents
EP1539151B1 (en) 2002-08-02 2009-03-18 Genesoft Pharmaceuticals, Inc. Biaryl compounds having anti-infective activity
RS20050106A (sr) * 2002-08-19 2007-11-15 Pfizer Products Inc., Kombinovana terapija hiperproliferativnih bolesti
WO2004039318A2 (en) 2002-10-25 2004-05-13 Genesoft Pharmaceuticals, Inc. Anti-infective biaryl compounds
CA2508769A1 (en) 2002-12-10 2004-06-24 Oscient Pharmaceuticals Corporation Antibacterial compounds having a (pyrrole carboxamide)-(benzamide)-(imidazole carboxamide) motif
BR0317548A (pt) 2002-12-19 2005-11-22 Pfizer Compostos de indazole e composições farmacêuticas para a inibição de proteìnas-cinases e métodos para o seu uso
JP2006516603A (ja) * 2003-01-27 2006-07-06 ファイザー・プロダクツ・インク イソチアゾール誘導体
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
WO2004096139A2 (en) 2003-04-24 2004-11-11 Incyte Corporation Aza spiro alkane derivatives as inhibitors of metalloproteases
EP1636585B2 (en) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
RS53476B (sr) 2003-07-18 2014-12-31 Amgen Fremont Inc. Sredstva za specifično vezivanje faktora rasta hepatocita
HRP20060073B1 (hr) 2003-07-23 2014-03-14 Bayer Healthcare Llc Fluoro supstituirana omega-karboksiaril difenil urea za lijeäśenje i prevenciju bolesti i stanja
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
EP1683785B1 (en) 2003-11-11 2013-10-16 Eisai R&D Management Co., Ltd. Urea derivative and process for producing the same
PL1723128T3 (pl) 2004-01-06 2013-04-30 Novo Nordisk As Pochodne heteroarylowe mocznika oraz ich zastosowanie jako aktywatory glukokinazy
ES2246687B2 (es) * 2004-02-11 2006-11-16 Miguel Muñoz Saez Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
WO2005081997A2 (en) * 2004-02-20 2005-09-09 The Scripps Research Institute Isothiazole based protein kinase inhibitors
WO2005102327A1 (en) * 2004-04-20 2005-11-03 Pfizer Products Inc. Dosage forms and methods of treatment using vegfr inhibitors
CN101010315A (zh) 2004-04-30 2007-08-01 拜耳制药公司 用于治疗癌症的取代的吡唑基脲衍生物
TW200538104A (en) * 2004-05-17 2005-12-01 Pfizer Prod Inc Phenyl derivatives for the treatment of abnormal cell growth
BRPI0513200A (pt) 2004-07-16 2008-04-29 Pfizer Prod Inc uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
JP4242911B2 (ja) 2004-08-26 2009-03-25 ファイザー・インク プロテインキナーゼ阻害薬としてのエナンチオピュアなアミノヘテロアリール化合物
CA2578023C (en) * 2004-08-26 2012-05-15 Pfizer Products Inc. Processes for the preparation of isothiazole derivatives
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
WO2006030941A1 (ja) 2004-09-13 2006-03-23 Eisai R & D Management Co., Ltd. スルホンアミド含有化合物の血管新生阻害物質との併用
WO2006030826A1 (ja) 2004-09-17 2006-03-23 Eisai R & D Management Co., Ltd. 医薬組成物
JP2008521900A (ja) 2004-11-30 2008-06-26 アムジエン・インコーポレーテツド キノリン及びキナゾリン類似体並びにがん治療のための医薬としてのその使用
US7429667B2 (en) * 2005-01-20 2008-09-30 Ardea Biosciences, Inc. Phenylamino isothiazole carboxamidines as MEK inhibitors
WO2006101925A2 (en) 2005-03-16 2006-09-28 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US20060216288A1 (en) * 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
RU2413735C2 (ru) 2005-03-31 2011-03-10 Эдженсис, Инк. Антитела и родственные молекулы, связывающиеся с белками 161p2f10b
NZ562234A (en) 2005-04-26 2009-09-25 Pfizer P-cadherin antibodies
WO2007006760A1 (en) 2005-07-08 2007-01-18 Novo Nordisk A/S Dicycloalkyl urea glucokinase activators
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
DK1933871T3 (da) 2005-09-07 2013-07-08 Amgen Fremont Inc Humane monoklonale antistoffer mod activin-receptor-lignende kinase-1
AU2006292278B2 (en) 2005-09-20 2012-03-08 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20080108664A1 (en) * 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
JP2009526050A (ja) * 2006-02-10 2009-07-16 アムジエン・インコーポレーテツド Ａｍｇ７０６の水和物形態
US7842836B2 (en) 2006-04-11 2010-11-30 Ardea Biosciences N-aryl-N'alkyl sulfamides as MEK inhibitors
CN101454004B (zh) * 2006-04-18 2013-12-04 阿迪亚生命科学公司 作为mek抑制剂的吡啶酮磺酰胺类和吡啶酮硫酰胺类
EP2258700A1 (en) 2006-05-09 2010-12-08 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
CA2652442C (en) 2006-05-18 2014-12-09 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
WO2007143600A2 (en) * 2006-06-05 2007-12-13 Incyte Corporation Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
CN101466691B (zh) * 2006-06-08 2011-07-27 伊莱利利公司 作为组ⅰ代谢型受体拮抗剂的取代的甲酰胺类化合物
US7932390B2 (en) 2006-06-29 2011-04-26 Hoffman-La Roche Inc. Substituted thieno[3,2-C]pyridine carboxylic acid derivatives
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
KR101472600B1 (ko) 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암에 대한 항종양제
AU2007338792B2 (en) 2006-12-20 2012-05-31 Amgen Inc. Substituted heterocycles and methods of use
EP2118069B1 (en) 2007-01-09 2014-01-01 Amgen Inc. Bis-aryl amide derivatives useful for the treatment of cancer
CN101600694A (zh) 2007-01-29 2009-12-09 卫材R&D管理有限公司 未分化型胃癌治疗用组合物
AU2008219166B2 (en) 2007-02-16 2013-05-16 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors
DK2116530T3 (da) * 2007-02-26 2013-01-28 Santen Pharmaceutical Co Ltd Nyt pyrrolderivat, der har en ureidgruppe og en aminobonylgruppe som substituenter
WO2008127707A1 (en) * 2007-04-13 2008-10-23 Dana Farber Cancer Institute, Inc. Receptor tyrosine kinase profiling
EP2851091B1 (en) 2007-04-13 2017-12-27 Dana-Farber Cancer Institute, Inc. Methods for treating cancer resistant to ERBB therapeutics
US8509487B2 (en) * 2007-04-19 2013-08-13 Avago Technologies General Ip (Singapore) Pte. Ltd. System and method for optically measuring a parameter of an object
MX2010001636A (es) 2007-08-14 2010-03-15 Hoffmann La Roche Derivados de pirazolo[3,4-d]-pirimidina como agentes antiproliferativos.
TWI595005B (zh) 2007-08-21 2017-08-11 安健股份有限公司 人類ｃ－ｆｍｓ抗原結合蛋白質
WO2009060945A1 (ja) 2007-11-09 2009-05-14 Eisai R & D Management Co., Ltd. 血管新生阻害物質と抗腫瘍性白金錯体との併用
US20100029491A1 (en) * 2008-07-11 2010-02-04 Maike Schmidt Methods and compositions for diagnostic use for tumor treatment
KR101596539B1 (ko) 2008-12-23 2016-02-22 제넨테크, 인크. 암 환자에서의 진단 목적용 방법 및 조성물
EP2400985A2 (en) 2009-02-25 2012-01-04 OSI Pharmaceuticals, LLC Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
JP2012519170A (ja) 2009-02-26 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519281A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
KR101523127B1 (ko) 2009-03-25 2015-05-26 제넨테크, 인크. 신규 항-α５β１ 항체 및 그의 용도
CA2766403A1 (en) 2009-07-13 2011-01-20 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
EP2459191A1 (en) 2009-07-31 2012-06-06 OSI Pharmaceuticals, LLC Mtor inhibitor and angiogenesis inhibitor combination therapy
WO2011033006A1 (en) 2009-09-17 2011-03-24 F. Hoffmann-La Roche Ag Methods and compositions for diagnostics use in cancer patients
WO2011073521A1 (en) 2009-12-15 2011-06-23 Petri Salven Methods for enriching adult-derived endothelial progenitor cells and uses thereof
ES2765657T3 (es) 2009-12-21 2020-06-10 Hoffmann La Roche Formulación farmacéutica de bevacizumab
CA3024216C (en) 2010-02-12 2021-03-30 Pfizer Inc. Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
AU2011223643A1 (en) 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20110217309A1 (en) 2010-03-03 2011-09-08 Buck Elizabeth A Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2011153224A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
ES2611479T3 (es) 2010-06-16 2017-05-09 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Anticuerpos contra endoplasmina y su uso
WO2011161217A2 (en) 2010-06-23 2011-12-29 Palacký University in Olomouc Targeting of vegfr2
CA2802644C (en) 2010-06-25 2017-02-21 Eisai R & D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
ES2979168T3 (es) 2010-07-23 2024-09-24 Univ Boston Inhibidores anti-DEspR como productos terapéuticos para inhibición de angiogénesis patológica e invasividad de células tumorales y para imagenología molecular y administración dirigida
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
GB201103578D0 (en) 2011-03-02 2011-04-13 Sabrepharm Ltd Dipyridinium derivatives
UA112539C2 (uk) 2011-03-03 2016-09-26 Новартіс Аг Спосіб одержання похідних 2-карбоксамідциклоаміносечовини
MY161199A (en) 2011-03-23 2017-04-14 Amgen Inc Fused tricyclic dual inhibitors of cdk 4/6 and flt3
CA2828946C (en) 2011-04-18 2016-06-21 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
EP2702173A1 (en) 2011-04-25 2014-03-05 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
US9416132B2 (en) 2011-07-21 2016-08-16 Tolero Pharmaceuticals, Inc. Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors
US9745288B2 (en) 2011-08-16 2017-08-29 Indiana University Research And Technology Corporation Compounds and methods for treating cancer by inhibiting the urokinase receptor
ES2623652T3 (es) 2011-12-28 2017-07-11 Allergan, Inc. Derivados de 3-fenil-5-ureidoisotiazol-4-carboximida y 3-amino-5-fenilisotiazol como inhibidores de cinasa
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
CN103508961B (zh) * 2012-06-26 2015-07-22 中美冠科生物技术（太仓）有限公司 抗肿瘤药物
US9505749B2 (en) 2012-08-29 2016-11-29 Amgen Inc. Quinazolinone compounds and derivatives thereof
JP6243918B2 (ja) 2012-10-16 2017-12-06 トレロ ファーマシューティカルズ， インコーポレイテッド Ｐｋｍ２調節因子およびそれらの使用方法
MX2015004979A (es) 2012-12-21 2015-07-17 Eisai R&D Man Co Ltd Forma amorfa de derivado de quinolina y metodo para su produccion.
BR112015022210A8 (pt) 2013-03-13 2018-01-23 Genentech Inc formulações de anticorpo
DK2970205T3 (da) 2013-03-14 2019-07-29 Tolero Pharmaceuticals Inc JAK2- og ALK2-inhibitorer og fremgangsmåder til anvendelse deraf
SG11201507316UA (en) 2013-03-14 2015-10-29 Panoptica Inc Ocular formulations for drug-delivery to the posterior segment of the eye
SG11201509278XA (en) 2013-05-14 2015-12-30 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
PT3126521T (pt) 2014-04-04 2019-06-27 Crown Bioscience Inc Taicang Gene de fusão hnf4g-rspo2
IL302218B2 (en) 2014-08-28 2024-10-01 Eisai R&D Man Co Ltd Methods for manufacturing high-purity lenvatinib and its derivatives
JP7072384B2 (ja) 2014-09-15 2022-05-20 ジェネンテック， インコーポレイテッド 抗体製剤
MA56220A (fr) 2014-09-17 2022-04-20 Panoptica Inc Formulations oculaires permettant l'administration de médicament et la protection du segment antérieur de l'oeil
US9353093B2 (en) 2014-10-07 2016-05-31 Allergan, Inc. Indole-1-carboxamides as kinase inhibitors
US9403803B2 (en) 2014-10-08 2016-08-02 Allergan, Inc. Indole-3-carboxamides as kinase inhibitors
US9371314B2 (en) 2014-10-09 2016-06-21 Allergan, Inc. Pyridyl benzothiophenes as kinase inhibitors
US9359336B2 (en) 2014-10-09 2016-06-07 Allergan, Inc. Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors
WO2016097918A1 (en) 2014-12-18 2016-06-23 Pfizer Inc. Pyrimidine and triazine derivatives and their use as axl inhibitors
EP3242934B1 (en) 2015-01-08 2021-08-18 The Board of Trustees of the Leland Stanford Junior University Factors and cells that provide for induction of bone, bone marrow, and cartilage
JP6792546B2 (ja) 2015-02-25 2020-11-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体の苦味抑制方法
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
JP6851978B2 (ja) 2015-04-20 2021-03-31 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド ミトコンドリアプロファイリングによるアルボシジブ応答の予測
JP6510075B2 (ja) 2015-05-18 2019-05-08 トレロ ファーマシューティカルズ， インコーポレイテッド バイオアベイラビリティが高いアルボシジブプロドラッグ
EP3311841B1 (en) 2015-06-16 2021-07-28 PRISM BioLab Co., Ltd. Anticancer agent
EP3331510A4 (en) 2015-08-03 2019-04-03 Tolero Pharmaceuticals, Inc. COMBINATION THERAPIES FOR THE TREATMENT OF CANCER
CN108135894B (zh) 2015-08-20 2021-02-19 卫材R&D管理有限公司 肿瘤治疗剂
GB2543550A (en) 2015-10-21 2017-04-26 Hox Therapeutics Ltd Peptides
US20180371551A1 (en) 2015-12-03 2018-12-27 Agios Pharmaceuticals, Inc. Mat2a inhibitors for treating mtap null cancer
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
CA3047557A1 (en) 2016-12-19 2018-06-28 Tolero Pharmaceuticals, Inc. Profiling peptides and methods for sensitivity profiling
EP3558955B1 (en) 2016-12-22 2021-08-11 Amgen Inc. Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
RU2750539C2 (ru) 2017-02-08 2021-06-29 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Фармацевтическая композиция для лечения опухоли
AU2018269996A1 (en) 2017-05-16 2019-11-21 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
EP3679040B1 (en) 2017-09-08 2022-08-03 Amgen Inc. Inhibitors of kras g12c and methods of using the same
WO2019055579A1 (en) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
AU2019262589B2 (en) 2018-05-04 2022-07-07 Amgen Inc. KRAS G12C inhibitors and methods of using the same
ES2995514T3 (en) 2018-05-04 2025-02-10 Amgen Inc Kras g12c inhibitors and methods of using the same
MX2020011907A (es) 2018-05-10 2021-01-29 Amgen Inc Inhibidores de kras g12c para el tratamiento de cancer.
ES2938987T3 (es) 2018-06-01 2023-04-18 Amgen Inc Inhibidores de KRAS G12c y métodos de uso de los mismos
MX2020012204A (es) 2018-06-11 2021-03-31 Amgen Inc Inhibidores de kras g12c para tratar el cáncer.
CA3100390A1 (en) 2018-06-12 2020-03-12 Amgen Inc. Kras g12c inhibitors encompassing piperazine ring and use thereof in the treatment of cancer
JP2021526130A (ja) 2018-06-12 2021-09-30 ブイティーブイ・セラピューティクス・エルエルシー インスリンまたはインスリン類似体と組み合わせたグルコキナーゼ活性化薬の治療的使用
CN112512597A (zh) 2018-07-26 2021-03-16 大日本住友制药肿瘤公司 用于治疗与acvr1表达异常相关的疾病的方法以及用于此的acvr1抑制剂
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
WO2020106640A1 (en) 2018-11-19 2020-05-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
EP3897670A4 (en) 2018-12-19 2022-09-07 Disarm Therapeutics, Inc. MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS
MA54546A (fr) 2018-12-20 2022-03-30 Amgen Inc Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
CA3123871A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Kif18a inhibitors
JP7676308B2 (ja) 2018-12-20 2025-05-14 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド
WO2020132651A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Kif18a inhibitors
CA3127502A1 (en) 2019-02-12 2020-08-20 Sumitomo Dainippon Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
WO2020180768A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
MX2021010323A (es) 2019-03-01 2021-12-10 Revolution Medicines Inc Compuestos bicíclicos de heterociclilo y usos de este.
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
WO2020198077A1 (en) 2019-03-22 2020-10-01 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprising pkm2 modulators and methods of treatment using the same
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
PH12021552922A1 (en) 2019-05-21 2022-04-04 Amgen Inc Solid state forms
AU2020324406A1 (en) 2019-08-02 2022-03-17 Amgen Inc. KIF18A inhibitors
JP7756070B2 (ja) 2019-08-02 2025-10-17 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤としてのピリジン誘導体
JP7640521B2 (ja) 2019-08-02 2025-03-05 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド
MX2022001295A (es) 2019-08-02 2022-02-22 Amgen Inc Inhibidores de kif18a.
AU2020369569A1 (en) 2019-10-24 2022-04-14 Amgen Inc. Pyridopyrimidine derivatives useful as KRAS G12C and KRAS G12D inhibitors in the treatment of cancer
WO2021091956A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
CA3159561A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
AU2020379731A1 (en) 2019-11-04 2022-05-05 Revolution Medicines, Inc. Ras inhibitors
MX2022005525A (es) 2019-11-08 2022-06-08 Revolution Medicines Inc Compuestos de heteroarilo bicíclicos y usos de estos.
AR120456A1 (es) 2019-11-14 2022-02-16 Amgen Inc Síntesis mejorada del compuesto inhibidor de g12c de kras
US12466825B2 (en) 2019-11-14 2025-11-11 Amgen Inc. Synthesis of KRAS G12C inhibitor compound
EP4065231A1 (en) 2019-11-27 2022-10-05 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
MX2022008305A (es) 2020-01-07 2022-08-08 Revolution Medicines Inc Dosificacion de inhibidores de shp2 y metodos de tratamiento del cancer.
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof
WO2021167840A1 (en) 2020-02-18 2021-08-26 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
CA3187757A1 (en) 2020-09-03 2022-03-24 Ethan AHLER Use of sos1 inhibitors to treat malignancies with shp2 mutations
PE20231207A1 (es) 2020-09-15 2023-08-17 Revolution Medicines Inc Derivados indolicos como inhibidores de ras en el tratamiento del cancer
CN117396472A (zh) 2020-12-22 2024-01-12 上海齐鲁锐格医药研发有限公司 Sos1抑制剂及其用途
CN117500811A (zh) 2021-05-05 2024-02-02 锐新医药公司 共价ras抑制剂及其用途
MX2023013085A (es) 2021-05-05 2023-11-16 Revolution Medicines Inc Inhibidores de ras.
PE20240089A1 (es) 2021-05-05 2024-01-16 Revolution Medicines Inc Inhibidores de ras para el tratamiento del cancer
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
TW202340214A (zh) 2021-12-17 2023-10-16 美商健臻公司 做為shp2抑制劑之吡唑并吡𠯤化合物
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
JP2025509217A (ja) 2022-03-07 2025-04-11 アムジエン・インコーポレーテツド ４－メチル－２－プロパン－２－イル－ピリジン－３－カルボニトリルを調製するための方法
CN119136806A (zh) 2022-03-08 2024-12-13 锐新医药公司 用于治疗免疫难治性肺癌的方法
CN120504682A (zh) 2022-06-10 2025-08-19 锐新医药公司 大环ras抑制剂
IL320217A (en) 2022-10-14 2025-06-01 Black Diamond Therapeutics Inc Methods for treating cancer using isoquinoline or 6-azaquinoline derivatives
WO2024140850A1 (zh) * 2022-12-28 2024-07-04 苏州必扬医药科技有限公司 一种蛋白酪氨酸激酶抑制剂及其医药用途
KR20250164828A (ko) 2023-03-30 2025-11-25 레볼루션 메디슨즈, 인크. Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도
AU2024253668A1 (en) 2023-04-07 2025-11-13 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
CN121100123A (zh) 2023-04-14 2025-12-09 锐新医药公司 Ras抑制剂的结晶形式
US20240352038A1 (en) 2023-04-14 2024-10-24 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025137507A1 (en) 2023-12-22 2025-06-26 Regor Pharmaceuticals, Inc. Sos1 inhibitors and uses thereof
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057416A (en) * 1976-06-18 1977-11-08 Fmc Corporation 3-Alkylthio-, 3-alkylsulfinyl-, and 3-alkylsulfonylisothiazole derivatives as herbicides
US4059433A (en) * 1976-06-18 1977-11-22 Fmc Corporation 3-Alkoxyisothiazole derivatives as herbicides
AU658646B2 (en) 1991-05-10 1995-04-27 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
MY109202A (en) 1992-07-10 1996-12-31 Nihon Nohyaku Co Ltd Isothiazole derivatives and processes for preparing the same as well as termite controlling agents comprising the same as active ingredient
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
IL112721A0 (en) 1994-03-10 1995-05-26 Zeneca Ltd Azole derivatives
DE4425642A1 (de) * 1994-07-20 1996-01-25 Merck Patent Gmbh Partiell fluorierte Benzolderivate
CA2306082A1 (en) 1997-10-27 1999-05-06 Agouron Pharmaceuticals, Inc. Substituted 4-amino-thiazol-2-y compounds as cdks inhibitors
UA60365C2 (uk) * 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
YU36403A (sh) * 2000-11-28 2006-08-17 Pfizer Products Inc. Soli izotiazol-4-karboksamida kao anti-hiperproliferacioni agensi
JP2006516603A (ja) * 2003-01-27 2006-07-06 ファイザー・プロダクツ・インク イソチアゾール誘導体

Also Published As

Publication number Publication date
AP1309A (en) 2004-09-14
MY130668A (en) 2007-07-31
TR200003478T2 (tr) 2001-03-21
US7790902B2 (en) 2010-09-07
BR9910900A (pt) 2001-02-13
PL198151B1 (pl) 2008-05-30
AU3342199A (en) 1999-12-20
SK17782000A3 (sk) 2001-08-06
US20010020034A1 (en) 2001-09-06
EP1084114B1 (en) 2004-09-08
CN1616386A (zh) 2005-05-18
KR100392434B1 (ko) 2003-07-22
UY25619A1 (es) 2000-02-23
NO20006071L (no) 2000-11-30
EA200001146A1 (ru) 2001-04-23
AR016725A1 (es) 2001-07-25
AP9901560A0 (en) 1999-06-30
NZ507009A (en) 2003-11-28
CN1303380A (zh) 2001-07-11
SI1084114T1 (en) 2005-02-28
TW561154B (en) 2003-11-11
BG104998A (en) 2001-07-31
OA11504A (en) 2004-05-17
DE69920009D1 (de) 2004-10-14
HUP0102422A3 (en) 2002-06-28
ES2226368T3 (es) 2005-03-16
CA2333703A1 (en) 1999-12-09
BG65104B1 (bg) 2007-02-28
CA2475113C (en) 2008-03-18
GT199900070A (es) 2000-11-10
WO1999062890A1 (en) 1999-12-09
IL138776A0 (en) 2001-10-31
HK1036982A1 (en) 2002-01-25
YU70100A (sh) 2004-07-15
GEP20084337B (enExample) 2008-03-25
EA004935B1 (ru) 2004-10-28
HN1999000080A (es) 1999-09-29
HUP0102422A2 (hu) 2002-05-29
US20030149048A1 (en) 2003-08-07
JP3735254B2 (ja) 2006-01-18
PE20000568A1 (es) 2000-07-08
CZ20004451A3 (en) 2001-05-16
JP2005002122A (ja) 2005-01-06
US7405218B2 (en) 2008-07-29
CA2333703C (en) 2005-06-14
NO20006071D0 (no) 2000-11-30
EP1084114A1 (en) 2001-03-21
US6235764B1 (en) 2001-05-22
HRP20000835A2 (en) 2001-12-31
ID27006A (id) 2001-02-22
MA26638A1 (fr) 2004-12-20
PT1084114E (pt) 2004-12-31
US20080300249A1 (en) 2008-12-04
CZ298559B6 (cs) 2007-11-07
SK286405B6 (sk) 2008-09-05
PL344691A1 (en) 2001-11-19
HRP20000835B1 (hr) 2008-01-31
TNSN99106A1 (fr) 2005-11-10
CO5011121A1 (es) 2001-02-28
ATE275553T1 (de) 2004-09-15
IS5690A (is) 2000-10-27
UA60365C2 (uk) 2003-10-15
KR20010052516A (ko) 2001-06-25
JP2002517384A (ja) 2002-06-18
CA2475113A1 (en) 1999-12-09
DE69920009T2 (de) 2005-09-15
BR9910900B1 (pt) 2013-09-17
NO318798B1 (no) 2005-05-09
PA8472301A1 (es) 2000-09-29
US6548526B2 (en) 2003-04-15
SA99200217B1 (ar) 2006-05-06
IS2269B (is) 2007-07-15
ZA993752B (en) 2000-12-04

Similar Documents

Publication Publication Date Title
CN1172918C (zh) 用作抗癌剂的异噻唑衍生物
CN1267431C (zh) 取代的喹唑啉衍生物及其在制备作为抑制剂的药物中的用途
CN1249039C (zh) 11β－羟基类固醇Ⅰ型脱氢酶抑制剂
CN1221533C (zh) 7－氨基－1h－吲哚衍生物
CN1033088C (zh) 新的噻唑基苯并呋喃衍生物的制备方法
CN1639141A (zh) 新的噻二唑和噁二唑及其作为磷酸二酯酶－7抑制剂的用途
CN1234708C (zh) 新的咪唑并三嗪酮类化合物及其应用
CN1391563A (zh) 治疗用喹唑啉衍生物
CN1070173C (zh) 用作药物的苯甲酰基胍衍生物
CN1507436A (zh) 用作放射增敏剂和化疗增敏剂的芳基和杂芳基脲chk1抑制剂
CN1575284A (zh) 作为激酶抑制剂的取代的三唑二胺衍生物
CN1990457A (zh) 作为cxc－趋化因子受体配体的3,4－二取代的环丁烯－1,2－二酮
CN1214339A (zh) 吡唑衍生物、其制备方法和在药物中的应用
CN1059142A (zh) 新的噻吩衍生物
CN1161334A (zh) 新的取代胍衍生物，其制备方法和其药物用途)
CN1646499A (zh) 稠合哒嗪衍生物化合物和含这些化合物作为活性成分的药物
CN1198804C (zh) 酰胺化合物及其用途
CN1620296A (zh) 作为Aurora激酶抑制剂的取代喹唑啉衍生物
CN1626516A (zh) 制备吡唑并嘧啶酮类化合物的新型中间体
CN1898240A (zh) 咪唑并吡嗪类酪氨酸激酶抑制剂
HK1042895A1 (zh) 三环吡唑衍生物
CN1602191A (zh) 化合物及其降低激素－敏感性脂肪酶活性的用途
CN1568187A (zh) 2h－2,3－二氮杂萘－1－酮和其使用方法
CN1258283A (zh) 新的环状二胺化合物及含有它的药物
CN1209809A (zh) 新化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1036982

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: AGOURON PHARMA

Free format text: FORMER OWNER: PFIZER PRODUCTS INC.

Effective date: 20090612

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20090612

Address after: New York, United States

Co-patentee after: Osi Pharm Inc.

Patentee after: Pfizer

Address before: American Connecticut

Patentee before: Pfizer Products Inc.

CX01 Expiry of patent term

Granted publication date: 20041027

CX01 Expiry of patent term